


Diferencias de género en la utilización de la
terapia de resincronización y desfibrilación:


¿cuestión de resultados o de oportunidades?

Concepción Alonso Martín
Hospital de Sant Pau. Barcelona

Registro Español de Desfibrilador Automático Implantable. XIV Informe Oficial de la Sección de Electrofisiología y Arritmias de la Sociedad Española de Cardiología (2017)



Registro Español de Desfibrilador Automático Implantable. XIV Informe Oficial de la Sección de Electrofisiología y Arritmias de la Sociedad Española de Cardiología (2017)



chusema2013

Miscelelánea



Trinorlense

32*...ES COSA DE HOMBRES*56



Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry

Guy Amit^{1,2*}, Mahmoud Suleiman³, Yuval Konstantino¹, David Luria^{1,4}, Mark Kazatsker⁵, Israel Chetboun⁶, Moti Haim⁶, Natalie Gavrielov-Yusim⁷, Ilan Goldenberg⁷, and Michael Glikson^{1,4} On behalf of the Israeli Working Group on Pacing and Electrophysiology

3544 implants
ICD and CRT-D

17% Women



Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry

Fredrik Gadler^{1,2}, Cinzia Valzania^{3*}, and Cecilia Linde^{1,2}

¹Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden; ²Department of Medicine, Karolinska Institutet, Stockholm, Sweden; and ³Cardiovascular Department, S. Orsola Malpighi Hospital, University of Bologna, Bologna, Italy

Received 9 March 2014; accepted after revision 11 August 2014; online publish-ahead-of-print 21 October 2014

1900 implants
ICD and CRT-D

20% Women



The gender difference of utilization of cardiac implantable electronic device in China: data from Arrhythmia Interventional Therapy Data Registry

Ruo-Han CHEN¹, Ke-Ping CHEN¹, Wei HUA¹, Jing XU², Lin CHEN³, Yang-Gang SU⁴, Xi SU⁵, Jian-Gang ZOU⁶, Ji YAN⁷, Jing-Feng WANG⁸, Bao-Peng TANG⁹, Mei-Xiang XIANG¹⁰, Shu ZHANG¹

1367 implants
ICD and CRT-D

30% Women



Europace (2014) **16**, 1175–1180
doi:10.1093/europace/euu015

CLINICAL RESEARCH

Sudden death and ICDs

Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry

Guy Amit^{1,2*}, Mahmoud Suleiman³, Yuval Konstantino¹, David Luria^{1,4}, Mark Kazatsker⁵, Israel Chetboun⁶, Moti Haim⁶, Natalie Gavrielov-Yusim⁷, Ilan Goldenberg⁷, and Michael Glikson^{1,4} On behalf of the Israeli Working Group on Pacing and Electrophysiology

Sex



Europace (2015) **17**, 69–77
doi:10.1093/europace/euu233

CLINICAL RESEARCH

Sudden death and ICDs

Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry

Fredrik Gadler^{1,2}, Cinzia Valzania^{3*}, and Cecilia Linde^{1,2}

¹Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden; ²Department of Medicine, Karolinska Institutet, Stockholm, Sweden; and ³Cardiovascular Department, S. Orsola Malpighi Hospital, University of Bologna, Bologna, Italy

Received 9 March 2014; accepted after revision 11 August 2014; online publish-ahead-of-print 21 October 2014

Journal of Geriatric Cardiology (2018) 15: 310–314
©2018 JGC All rights reserved; www.jgc301.com



Research Article

• Open Access •

The gender difference of utilization of cardiac implantable electronic device in China: data from Arrhythmia Interventional Therapy Data Registry

Ruo-Han CHEN¹, Ke-Ping CHEN¹, Wei HUA¹, Jing XU², Lin CHEN³, Yang-Gang SU⁴, Xi SU⁵, Jian-Gang ZOU⁶, Ji YAN⁷, Jing-Feng WANG⁸, Bao-Peng TANG⁹, Mei-Xiang XIANG¹⁰, Shu ZHANG¹

Gender



REAL ACADEMIA ESPAÑOLA

sexo

Del lat. *sexus*.

1. m. Condición orgánica, masculina o femenina, de los animales y las plantas.
2. m. Conjunto de seres pertenecientes a un mismo **sexo**. **Sexo masculino, femenino.**
3. m. Órganos sexuales.
4. m. Actividad sexual. **Está obsesionado con el sexo.**


género

Del lat. *genus, -ĕris*.

1. m. Conjunto de seres que tienen uno o varios caracteres comunes.
2. m. Clase o tipo a que pertenecen personas o cosas. **Ese género de bromas no me gusta.**
3. m. Grupo al que pertenecen los seres humanos de cada sexo, entendido este desde un punto de vista sociocultural en lugar de exclusivamente biológico.

Efecto de las hormonas sexuales

| Lugar | Andrógenos | Estrógenos |
|---------------------------|------------------|----------------|
| Corazón | | |
| Contractilidad | ↑ | ↔ |
| Masa ventrículo izquierdo | ↑ | ↓ |
| Fibrosis | ↑ | ↓ |
| Vasos | Vasoconstricción | Vasodilatación |
| Músculo esquelético | ↑ | ↓ |
| Riñón | | |
| Glomeruloesclerosis | ↑ | ↓ |
| Renina | ↑ | ↓ |



Progressive manifestations of ischemic heart disease


Acute effects of sex steroid hormones on susceptibility to cardiac arrhythmias: a simulation study.

Estradiol:


↑ Susceptibility to cardiac arrhythmias

Testosterone
Progesterone

↓ Susceptibility to cardiac arrhythmias



Registro Español de Desfibrilador Automático Implantable. XIV Informe Oficial de la Sección de Electrofisiología y Arritmias de la Sociedad Española de Cardiología (2017)



2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

| | | |
|--|---|---|
| <p>Secondary prevention An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status.</p> | I | A |
| <p>Primary prevention An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA Class II–III), and an LVEF \leq35% despite \geq3 months of OMT, provided they are expected to survive substantially longer than one year with good functional status, and they have:</p> <ul style="list-style-type: none"> • IHD (unless they have had an MI in the prior 40 days – see below). • DCM. | | |
| | I | A |
| | I | B |


To reduce the risk of sudden death and all cause mortality

Los inicios


Effectiveness of Implantable Cardioverter-Defibrillators for the Primary Prevention of Sudden Cardiac Death in Women With Advanced Heart Failure

A Meta-analysis of Randomized Controlled Trials

Mortality Men




Mortality Women



Effectiveness of Implantable Cardioverter-Defibrillators for the Primary Prevention of Sudden Cardiac Death in Women With Advanced Heart Failure


A Meta-analysis of Randomized Controlled Trials

Mortality Men



ICD therapy for PP of SCD in women *does not* reduce all-cause mortality


Mortality Women



Women are underrepresented in RT


| ICD Trials | Subjects | % females | HR for mortality |
|--------------------|----------|-----------|--|
| AVID (sec prevent) | 1885 | 22 | M 14.4% mortality W 15,5% mortality (24.5% en pat without ICD) |
| MADIT I | 196 | 8 | 54% RR global not by sex |
| MADIT II | 1232 | 16 | M 0.66 W 0.57 ns |
| SCD-HeFT | 2521 | 23 | M 0.73 W 0.96 ns |
| MUSTT | 704 | 10 | M 0.79 W 0.68 ns |
| DEFINITE | 458 | 29 | M 0.49 W 1.14 ns |

MADIT II subgroup analysis



PATIENTS AT RISK

| | | | | |
|--------------|-----|-----------|-----------|-----------|
| Conventional | 73 | 42 (0.14) | 16 (0.30) | 5 (0.35) |
| ICD | 119 | 84 (0.09) | 47 (0.15) | 20 (0.23) |





PATIENTS AT RISK

| | | | | |
|--------------|-----|------------|------------|-----------|
| Conventional | 417 | 287 (0.09) | 154 (0.20) | 60 (0.30) |
| ICD | 623 | 419 (0.09) | 227 (0.16) | 90 (0.22) |



No differences in mortality rates

Influence of Gender on Arrhythmia Characteristics and Outcome in the Multicenter UnSustained Tachycardia Trial




Inclusion criteria: CAD, FE<40% and NSVT

Influence of Gender on Arrhythmia Characteristics and Outcome in the Multicenter UnSustained Tachycardia Trial



Inclusion criteria: CAD, FE<40% and NSVT

Primary Prevention with Defibrillator Therapy in Women: Results from the Sudden Cardiac Death in Heart Failure Trial



23% Women

TABLE 3
Mortality Randomized Treatment Comparisons by Gender


| | Overall Mortality | | | Adjusted HR (95% CI) | |
|-------|-------------------|-----------------|---------|----------------------|---------------------|
| | ICD | Amioda- rone | Placebo | ICD vs. placebo | Amio vs. placebo |
| Women | 18.9% | 22.3% | 21.4% | 0.90 (0.56, 1.43) | 1.11 (0.71, 1.73) |
| Men | 22.8% | 30.6% | 31.0% | 0.71 (0.57, 0.88) | 1.02 (0.84, 1.25) |

Figure 1. Mortality by gender. Overall mortality was lower in women than in men ($P = 0.001$).

No benefit of ICD in women:
Why?


Ischemic vs non-ischemic

Registro Español de Desfibrilador Automático Implantable. XIV Informe Oficial de la Sección de Electrofisiología y Arritmias de la Sociedad Española de Cardiología (2017)




- Cardiopatía isquémica
- Cardiopatías congénitas
- MCAVD
- Miocardiopatía dilatada
- Síndrome de Brugada
- Síndrome de QT largo
- Miocardiopatía hipertrófica
- Valvulopatía

Enfermedad coronaria más prevalente en el varón




Número de altas de enfermedad coronaria entre 1977 y 2010

Ischemic heart disease




● Men

Myocardial infarction and fatal CAD




● Women

Importancia de la edad y comorbilidades




EF < 35%

Implantes según la FE




The EuroHeart Failure survey programme— a survey on the quality of care among patients with heart failure in Europe



UIC H. Sant Pau

Visitas en UIC entre 2010-2015




De qué se mueren los pacientes?


Important Differences in Mode of Death Between Men and Women With Heart Failure Who Would Qualify for a Primary Prevention Implantable Cardioverter-Defibrillator

N 8337;
20% Women

Sudden Death



Heart Failure Death




NYHA II-III; FE < 35%.

Ischemic cardiomyopathy: 43% Women, 59% Men

Cardiac Resynchronization Therapy Is More Effective in Women Than in Men

The MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) Trial



Men RR 28%

Women are underrepresented in RT

| CRT Trials | Subjects | % females | HR for events |
|------------|----------|-----------|------------------------------|
| COMPANION | 1520 | 33 | M 0.63 W 0.58 ns |
| CARE-HF | 813 | 27 | M 0.62 W 0.64 |
| MADIT-CRT | 1820 | 25 | M 0.76 W 0.37 |
| RAFT | 1798 | 17 | M 0,82 W 0,52 |
| MIRACLE | 453 | 32 | W longer time to HF or death |

Después de los estudios
randomizados...la vida real...



Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women—Data From a Multicenter French Registry

N: 5539

Women 837 **(15,1%)**

Rui Providência, MD, PhD; Eloi Marijon, MD, PhD; Pier D. Lambiase, PhD; Abdeslam Bouzeman, MD; Pascal Defaye, MD; Didier Klug, MD, PhD; Denis Amet, MD; Marie-Cécile Perier, MPH; Daniel Gras, MD; Vincent Algalarrondo, MD, PhD; Jean-Claude Deharo, MD, PhD; Christophe Leclercq, MD, PhD; Laurent Fauchier, MD, PhD; Dominique Babuty, MD, PhD; Pierre Bordachar, MD, PhD; Nicolas Sadoul, MD, PhD; Olivier Piot, MD; Serge Boveda, MD on behalf of the DAI-PP Investigators*

Similar mortality



| Group | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
|--------------|------|------|------|------|-----|-----|-----|
| ♂ with ICD | 2446 | 1793 | 1456 | 1073 | 772 | 519 | 332 |
| ♂ with CRT-D | 2214 | 1902 | 1432 | 1012 | 668 | 449 | 246 |
| ♀ with ICD | 325 | 266 | 211 | 163 | 109 | 66 | 37 |
| ♀ with CRT-D | 506 | 398 | 309 | 219 | 137 | 92 | 35 |


| Group | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
|--------------|------|------|------|------|-----|-----|-----|
| ♂ with ICD | 2446 | 1793 | 1456 | 1073 | 772 | 519 | 332 |
| ♂ with CRT-D | 2214 | 1902 | 1432 | 1012 | 668 | 449 | 246 |
| ♀ with ICD | 325 | 266 | 211 | 163 | 109 | 66 | 37 |
| ♀ with CRT-D | 506 | 398 | 309 | 219 | 137 | 92 | 35 |

Survival in Women Versus Men Following Implantation of Pacemakers, Defibrillators, and Cardiac Resynchronization Therapy Devices in a Large, Nationwide Cohort

N: 269,471


Niraj Varma, MA, DM, FRCP; Suneet Mittal, MD, FHRS; Julie B. Prillinger, PhD; Jeff Snell, AB; Nirav Dalal, MS; Jonathan P. Piccini, MD, MHSc, FHRS

Postimplant survival by Sex




--- Number at Risk ---

| | | | | | | |
|--------|--------|--------|--------|--------|--------|-------|
| Female | 22,080 | 20,695 | 18,970 | 11,647 | 4,927 | 587 |
| Male | 62,934 | 58,944 | 53,425 | 33,431 | 15,041 | 1,686 |



--- Number at Risk ---

| | | | | | | |
|--------|--------|--------|--------|--------|-------|-----|
| Female | 17,130 | 16,059 | 14,544 | 8,545 | 3,382 | 293 |
| Male | 44,345 | 40,746 | 36,033 | 20,749 | 8,007 | 751 |




--- Number at Risk ---

| | | | | | |
|--------|-------|-------|-------|-------|-----|
| Female | 3,382 | 3,156 | 2,825 | 1,112 | 84 |
| Male | 4,524 | 4,092 | 3,571 | 1,370 | 108 |

Experiencia H. Sant Pau

823 pacientes en seguimiento




Survival in Women Versus Men Following Implantation of Pacemakers, Defibrillators, and Cardiac Resynchronization Therapy Devices in a Large, Nationwide Cohort

N: 269,471

Niraj Varma, MA, DM, FRCP; Suneet Mittal, MD, FHRS; Julie B. Prillinger, PhD; Jeff Snell, AB; Nirav Dalal, MS; Jonathan P. Piccini, MD, MHSc, FHRS

Distribution of patients with cardiac implantable devices



The power of women




Y el futuro...

Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator

All 311.009
Women 30%

Neal A. Chatterjee¹, Rasmus Borgquist², Yuchiao Chang³, Jennifer Lewey⁴, Vicki A. Jackson⁵, Jagmeet P. Singh¹, Joshua P. Metlay³, and Charlotta Lindvall^{6*}



Sex-specific precision medicine: targeting CRT-D and other cardiovascular interventions to those most likely to benefit

Viviany R. Taqueti¹ and C. Noel Bairey Merz^{2*}

Conclusiones

¿Cuestión de resultados?

Los resultados avalan el uso del DAI y la CRT en mujeres

¿Cuestión de oportunidades?

Para los médicos

